Medical Condition News

RSS

ITCs in vegetables appear to target and block p53 gene linked with cancer

Scientists are reporting discovery of a potential biochemical basis for the apparent cancer-fighting ability of broccoli and its veggie cousins. They found for the first time that certain substances in the vegetables appear to target and block a defective gene associated with cancer.

10 Mar 2011

NSW selects ZOLL AED Plus devices for Rural Fire Service stations

ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that it has received an award from the Government of NSW Australia to provide 5450 AED Plus devices for installation on all Rural Fire Service stations deployed throughout the State of New South Wales.

10 Mar 2011

Study: Alcohol abuse impacts quality of life for patients after liver transplant

A history of alcohol abuse significantly impacts quality of life for patients after liver transplant, according to researchers at Henry Ford Hospital.

10 Mar 2011

FDA approves BENLYSTA for active, autoantibody-positive systemic lupus erythematosus

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced that the U.S. Food and Drug Administration has approved BENLYSTA® (belimumab) for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy.

10 Mar 2011

Vascular disorder of the brain most frequently misdiagnosed as multiple sclerosis

A devastating vascular disorder of the brain called CADASIL, which strikes young adults and leads to early dementia, often is misdiagnosed as multiple sclerosis, Loyola University Health System researchers report.

10 Mar 2011

TARIS commences LiRIS Phase 1B clinical study in interstitial cystitis

TARIS Biomedical, a specialty pharmaceutical company pioneering the development of innovative, targeted therapies using drug delivery to treat bladder diseases with high unmet medical need, announced that it has initiated a Phase 1B clinical study in patients with interstitial cystitis (IC). The study will evaluate the safety and tolerability of TARIS' innovative product candidate LiRIS® in patients suffering from moderate-to-severe IC.

10 Mar 2011

Study reveals flexibility of neuronal processes underlying conscious perception

Our brains process many more stimuli than we become aware of. Often images enter our brain without being noticed: visual information is being processed, but does not reach consciousness, that is, we do not have an impression of it. Then, what is the difference between conscious and unconscious perception, and can both forms of perception be changed through practice?

10 Mar 2011

FDA accepts Merck's SAFLUTAN NDA for standard review

Merck, known as MSD outside the United States and Canada, announced today that the New Drug Application for SAFLUTAN, Merck's investigational preservative-free prostaglandin analogue ophthalmic solution, has been accepted for standard review by the U.S. Food and Drug Administration.

10 Mar 2011

CUBN gene mutation linked with albuminuria in individuals with or without diabetes

A team of researchers from the United States and Europe has identified a single genetic mutation in the CUBN gene that is associated with albuminuria both with and without diabetes. Albuminuria is a condition caused by the leaking of the protein albumin into the urine, which is an indication of kidney disease.

9 Mar 2011

EDT receives European approval for XEPLION injection to treat schizophrenia

Elan Drug Technologies, the drug delivery unit of Elan Corporation, plc, today announced that the first injectable product using EDT's NanoCrystal technology has been approved by the European Commission.

9 Mar 2011

KineMed extends collaboration with BMY to identify and characterize Alzheimer's biomarkers

KineMed, Inc. announced today the extension of its collaboration with Bristol-Myers Squibb in the area of Alzheimer's disease and other neurodegenerative conditions.

9 Mar 2011

NeuroDerm commences ND0611 Phase I/II trial to treat Parkinson's disease

NeuroDerm, Ltd. announced today the enrollment of the first group of patients in its Phase I/II clinical trial of ND0611, a new patch for the treatment of Parkinson's disease.

9 Mar 2011

U.S. FDA approves Hospira's docetaxel to treat variety of cancers

Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced U.S. Food and Drug Administration approval of docetaxel. The medication is a generic version of Sanofi-Aventis's Taxotere, and Hospira expects to launch the product later this month.

9 Mar 2011

Auxilium completes patient enrollment in XIAFLEX phase III trial against Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced it has reached the target enrollment for the double-blind placebo-controlled phase III program of XIAFLEX for the treatment of Peyronie's disease.

9 Mar 2011

Camp STAR to offer evidence-based therapy for children with ADHD

Camp STAR, the Chicago area's only summer camp offering evidence-based therapy for children with Attention Deficit/Hyperactivity Disorder and other behavioral, emotional and social difficulties, begins its fourth season in June.

9 Mar 2011

Older men have higher risk of melanoma: Australian study

Health experts warn that the rates of skin cancer – melanoma, is on the rise among elderly Victorians. This came out as new figures were released yesterday by Cancer Council Victoria that showed that Victorians aged over 55 accounted for two-thirds of melanoma diagnoses, and rural men were at highest risk. In 2008 a total of 2217 Victorians were diagnosed with melanoma and 279 people died. Skin cancer rates have increased by 400 per cent in the past 26 years among older males.

9 Mar 2011

Human Genome Sciences receives FDA approval for Benlysta to treat lupus

The U.S. Food and Drug Administration today approved Benlysta to treat patients with active, autoantibody-positive lupus who are receiving standard therapy, including corticosteroids, antimalarials, immunosuppressives, and nonsteroidal anti-inflammatory drugs.

9 Mar 2011

ERYtech Pharma completes patient enrollment in GRASPA Phase II trial against ALL

ERYtech Pharma announces the early completion of the enrollment and safety follow-up a Phase II clinical trial for GRASPA. This open-labeled trial introduced GRASPA in a first-line treatment for Acute Lymphoblastic Leukemia in patients older than 55 years.

9 Mar 2011

Atherotech announces Sponsorship Agreement with NLA

Aiming to boost advanced lipoprotein testing in lipid education and management, Atherotech Diagnostics Lab announces its Sponsorship Agreement with the National Lipid Association.

9 Mar 2011

Adamis submits APC-100 IND to FDA for treatment of prostate cancer

Adamis Pharmaceuticals Corporation announced today that it has recently submitted to the FDA an Investigational New Drug application for APC-100 to treat prostate cancer.

9 Mar 2011